Faculty Collaboration Database

Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer 2009 Jan;7(1):39-42

Date

02/14/2009

Pubmed ID

19213667

DOI

10.3816/CGC.2009.n.007

Scopus ID

2-s2.0-65249089759 (requires institutional sign-in at Scopus site)   15 Citations

Abstract

BACKGROUND: Cytotoxic chemotherapy has not been well investigated in non-clear-cell renal cell carcinoma (RCC). A phase II study was thus conducted to assess the efficacy of carboplatin and paclitaxel in such patients.

PATIENTS AND METHODS: Patients were treated with carboplatin (area under the curve of 6) and paclitaxel 225 mg/m2 every 21 days and assessed for measurable disease response every 2 cycles. An initial 20 patients were planned to be enrolled to rule out a null hypothesized 15% response rate.

RESULTS: Seventeen patients were enrolled, of which 16 patients had papillary and 1 had collecting duct histology. The patient with collecting duct histology had a complete response, but no responses were observed in patients with papillary histology and the trial was thus terminated early. Toxicities were as expected for the carboplatin and paclitaxel regimen.

CONCLUSION: Carboplatin and paclitaxel is not an active regimen in patients with metastatic papillary RCC. Future studies should explore the role of this or similar regimens in collecting duct carcinoma.

Author List

Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF

Author

Kathryn A. Bylow MD Associate Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Carcinoma, Papillary
Carcinoma, Renal Cell
Female
Humans
Kidney Neoplasms
Male
Middle Aged
Paclitaxel
Prognosis
Survival Rate
Treatment Outcome